Medicenna Therapeutics Corp.
NASDAQ: MDNA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Fahar Merchant
- Employees
- 16
- Headquarters
- Toronto, Canada
- IPO year
- 2017
- Website
- https://www.medicenna.com
Loading MDNA…
Loading profile data…Frequently asked questions about MDNA
What does Medicenna Therapeutics Corp. (MDNA) do?
Medicenna Therapeutics Corp. is an immunotherapy company dedicated to discovering and commercializing innovative Superkines and "empowered Superkines" for the treatment of various cancers and other ailments. The company's primary therapeutic candidate, MDNA55 (an interleukin-4 (IL-4) EC), has successfully completed a Phase IIb clinical trial for...
Where does MDNA trade?
Medicenna Therapeutics Corp. (MDNA) trades on the NASDAQ Capital Market.
What sector is MDNA in?
Medicenna Therapeutics Corp. (MDNA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Medicenna Therapeutics Corp.?
Fahar Merchant is the chief executive officer of Medicenna Therapeutics Corp. (MDNA).
Where is Medicenna Therapeutics Corp. headquartered?
Medicenna Therapeutics Corp. is headquartered in Canada.
Does MDNA pay a dividend?
Medicenna Therapeutics Corp. (MDNA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did MDNA go public?
Medicenna Therapeutics Corp. (MDNA) completed its initial public offering in 2017.